Compositions and methods for modulating angiopoietin-like 3 expression
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
1. A compound, comprising a single stranded modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides and wherein the nucleobase sequence of the modified oligonucleotide comprises at least 8 contiguous nucleobases complementary to an equal length portion of nucleobases 1140 to 1159 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO: 1; wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide by a conjugate linker; and wherein the conjugate group comprises:
or a salt thereof.
2. The compound or salt of claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 85% complementary to SEQ ID NO: 1.
3. The compound or salt of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound or salt of claim 3 , wherein the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.
5. The compound or salt of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.
6. The compound or salt of claim 5 , wherein the at least one modified sugar is selected from the group consisting of a bicyclic sugar, a 2′-O-methoxyethyl modified sugar, a constrained ethyl modified sugar, a 3′-fluoro-HNA, and a 4′-(CH 2 ) n —O-2′ bridge, wherein n is 1 or 2.
7. The compound or salt of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.
8. The compound or salt of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.
9. The compound or salt of claim 1 , wherein the modified oligonucleotide comprises:
a gap segment consisting of linked deoxynucleosides;
a 5′ wing segment consisting of linked nucleosides;
a 3′ wing segment consisting of linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
10. The compound or salt claim 1 , wherein the modified oligonucleotide comprises:
a gap segment consisting of ten linked deoxynucleosides;
a 5′ wing segment consisting of five linked nucleosides;
a 3′ wing segment consisting of five linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar, and wherein each cytosine residue is a 5-methylcytosine.
11. The compound or salt of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage.
12. The compound or salt of claim 10 , wherein the modified oligonucleotide consists of 20 linked nucleosides.
13. The compound or salt of claim 1 , wherein the conjugate group comprises a cleavable moiety selected from the group consisting of a phosphodiester, an amide, and an ester.
14. A pharmaceutical composition comprising the compound or salt of claim 1 and a pharmaceutically acceptable carrier or diluent.
15. A method for treating a disease, disorder, or condition related to elevated ANGPTL3 in a human in need thereof, comprising administering to the human a therapeutically effective amount of the compound or salt of claim 1 , wherein the disease, disorder, or condition is a cardiovascular and/or metabolic disease, disorder, or condition.
16. The method of claim 15 , wherein the disease, disorder or condition is selected from the group consisting of atherosclerosis, hepatic steatosis, obesity, diabetes, dyslipidemia, coronary heart disease, non-alcoholic fatty liver disease (NAFLD), hyperfattyacidemia, and metabolic syndrome.
17. The method of claim 16 , wherein the disease, disorder, or condition is hepatic steatosis and wherein the hepatic steatosis is nonalcoholic steatohepatitis (NASH).
18. The method of claim 16 , wherein the disease, disorder, or condition is dyslipidemia, wherein the dyslipidemia is selected from the group consisting of hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
19. The compound or salt of claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1.
20. The compound or salt of claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to SEQ ID NO: 1.
21. The compound or salt of claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO: 1.
22. The method of claim 15 , wherein the compound or salt is present in a pharmaceutically acceptable composition.